Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
393
Recruiting Now
393
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT06214156 Phase 1, Phase 2
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Condition
Advanced Melanoma
Enrollment
42 pts
Location
China
Sponsor
Shanghai Pharmaceuticals Holdi
NCT07353645 Phase 1, Phase 2
Recruiting
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic...
Condition
Colorectal Cancer
Enrollment
49 pts
Location
China
Sponsor
The Affiliated Nanjing Drum To
NCT07680595 Phase 1, Phase 2
Recruiting
Prospective Management of Plaque Instability With Statins and Extra Folic Acid
Condition
Carotid Atherosclerotic Plaque
Enrollment
180 pts
Location
China
Sponsor
Ruijin Hospital
NCT06324357 Phase 1, Phase 2
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in...
Condition
Metastatic Breast Cancer
Enrollment
768 pts
Location
United States, Belgium, China
Sponsor
Boehringer Ingelheim
NCT06746519 Phase 1, Phase 2
Recruiting
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leuk...
Condition
Acute Myeloid Leukemia
Enrollment
135 pts
Location
China
Sponsor
Chen Suning
NCT06754930 Phase 1, Phase 2
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies ...
Condition
Non-small Cell Lung Cancer (NSCLC)
Enrollment
400 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT07662681 Phase 1, Phase 2
Recruiting
Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies
Condition
Head and Neck Cancer
Enrollment
40 pts
Location
China
Sponsor
Shanghai Ninth People's Hospit
NCT06526819 Phase 1, Phase 2
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
Condition
Solid Tumor
Enrollment
120 pts
Location
United States, Japan
Sponsor
Sumitomo Pharma America, Inc.
NCT04750928 Phase 1, Phase 2
Recruiting
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Typ...
Condition
Neurofibromatosis 1
Enrollment
55 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07641036 Phase 1, Phase 2
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Condition
Cholangiocarcinoma
Enrollment
30 pts
Location
China
Sponsor
Beijing Biotech
NCT05508009 Phase 1, Phase 2
Recruiting
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients W...
Condition
SIOD
Enrollment
12 pts
Location
United States
Sponsor
Alice Bertaina
NCT07041801 Phase 1, Phase 2
Recruiting
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal ...
Condition
Systemic Lupus Erythematosus (SLE)
Enrollment
58 pts
Location
China
Sponsor
Shenzhen Beike Bio-Technology
NCT06859775 Phase 1, Phase 2
Recruiting
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervi...
Condition
Recurrent or Metastatic Cervical Cancer
Enrollment
100 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT07473167 Phase 1, Phase 2
Recruiting
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell No...
Condition
Relapsed Large B-cell Lymphoma
Enrollment
98 pts
Location
South Korea
Sponsor
TICAROS Co., Ltd.
NCT06739265 Phase 1, Phase 2
Recruiting
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Condition
Peripheral T-cell Lymphoma
Enrollment
68 pts
Location
China
Sponsor
Peking Union Medical College H
NCT06011109 Phase 1, Phase 2
Recruiting
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizu...
Condition
Glioma
Enrollment
30 pts
Location
United States
Sponsor
Aveta Biomics, Inc.
NCT06548230 Phase 1, Phase 2
Recruiting
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without...
Condition
Myelodysplastic Syndrome(MDS)
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05110742 Phase 1, Phase 2
Recruiting
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cel...
Condition
Hematological Malignancy
Enrollment
64 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06262139 Phase 1, Phase 2
Recruiting
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate C...
Condition
MRI Scan
Enrollment
12 pts
Location
United States
Sponsor
Songqi Gao
NCT04373057 Phase 1, Phase 2
Recruiting
Prebiotic Galacto-oligosaccharide and Acute GVHD
Condition
Acute GVHD
Enrollment
128 pts
Location
United States
Sponsor
University of Kansas Medical C
NCT06025630 Phase 1, Phase 2
Recruiting
Targeting Endoplasmic Reticulum Stress in Human Hypertension
Condition
Hypertension
Enrollment
70 pts
Location
United States
Sponsor
University of North Texas Heal
NCT07249905 Phase 1, Phase 2
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different T...
Condition
Lymphoma
Enrollment
180 pts
Location
Australia
Sponsor
ModeX Therapeutics, An OPKO He
NCT05839275 Phase 1, Phase 2
Recruiting
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localize...
Condition
High-Risk Localized Soft Tissue Sarcoma
Enrollment
52 pts
Location
China
Sponsor
Fudan University
NCT06948981 Phase 1, Phase 2
Recruiting
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-...
Condition
Hematological Malignancy (Leukemia- Lymphoma)
Enrollment
46 pts
Location
China
Sponsor
Grit Biotechnology
NCT06554795 Phase 1, Phase 2
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
360 pts
Location
United States, Australia, China
Sponsor
DualityBio Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology